Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07170787 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Name: A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors — clinical trial record (NCT07170787)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Started2025-10-15

View on ClinicalTrials.gov ↗

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

10 trials monitored

See all monitored trials

This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.

Trial Details

NCT Number	NCT07170787
Lead Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions	Advanced Solid Tumors
Enrollment	104 participants
Start Date	2025-10-15
Primary Completion	2029-02 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2025-09-12